| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 26th August 2020 | Joseph C Galante | 225 | Open or private purchase | $3.29 | $740.25 |
| 21st August 2020 | Joseph C Galante | 375 | Open or private purchase | $3.35 | $1,256.25 |
| 14th August 2020 | Joseph C Galante | 375 | Open or private purchase | $3.44 | $1,290.00 |
| 7th August 2020 | Joseph C Galante | 375 | Open or private purchase | $3.42 | $1,282.50 |
| 31st July 2020 | Joseph C Galante | 375 | Open or private purchase | $3.26 | $1,222.50 |
| 24th July 2020 | Joseph C Galante | 375 | Open or private purchase | $3.33 | $1,248.75 |
| 17th July 2020 | Joseph C Galante | 375 | Open or private purchase | $3.29 | $1,233.75 |
| 10th July 2020 | Joseph C Galante | 375 | Open or private purchase | $3.31 | $1,241.25 |
| 2nd July 2020 | Joseph C Galante | 300 | Open or private purchase | $3.34 | $1,002.00 |
| 26th June 2020 | Joseph C Galante | 375 | Open or private purchase | $3.37 | $1,263.75 |
Cumberland Pharmaceuticals
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
Cumberland Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of prescription products. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.
Ticker: CPIX
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
SEC Central Index Key (CIK): 1087294
Employees: 80
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $27 M (-2%)
Inventory, Net: $8 M (0%)
Other Assets, Current: $2 M (-24%)
Assets, Current: $46 M (-8%)
Property, Plant and Equipment, Net: $632 Th (-15%)
Other Assets, Noncurrent: $3 M (-10%)
Assets: $98 M (-6%)
Accounts Payable, Current: $11 M (8%)
Liabilities, Current: $23 M (-6%)
Liabilities: $49 M (-8%)
Common Stock, Value, Issued: $49 M (-1%)
Common Stock, Shares, Issued: $15 M (0%)
Retained Earnings (Accumulated Deficit): $766 Th (-36%)
Stockholders' Equity (Parent): $48 M (-5%)
Liabilities and Equity: $98 M (-6%)
Revenue: $10 M (0%)
Cost of Revenue: $3 M (-38%)
Research and Development: $1 M (-54%)
Sales and Marketing: $4 M (-48%)
General and Administrative Expenses: $2 M (-48%)
Operating Income/Loss: $2 M (-53%)
Income before taxes: $2 M (-52%)
Provision for income taxes: $7 Th (-82%)
EPS (basic): $0.06 (-53%)
EPS (diluted): $0.06 (-53%)
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020